Focus: Labcorp is a large-scale CRO and diagnostic services company with 70,000 employees and $12.2B in FY 2025 revenue, operating across clinical trial services, drug development, and laboratory testing globally.
Profile data last refreshed 22h ago · AI intelligence enriched 2w ago
Hot — 4958 jobs added in 30d
Net +3331 (4958 new, 1627 removed). Aggressive expansion phase.
4 recent layoff filings (12 mo) — 354 affected
Source: state DOL filings via Big Local News
Strong for pharma professionals seeking CRO scale and trial infrastructure exposure, but recent layoffs and margin compression warrant scrutiny of department stability before joining.
Help build intelligence for Labcorp
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Labcorp's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Labcorp Holdings (LH) Expands HPV Testing While Teaming With Regulators On Drug Safety - Yahoo Finance
Labcorp Holdings (LH) Expands HPV Testing While Teaming With Regulators On Drug Safety Yahoo Finance
8-K Filing: ManpowerGroup Inc. (MAN) (CIK 0000871763) — EX-99.1
EX-99.1
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential - PR Newswire
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential PR Newswire
The FDA, Labcorp and Charles River aim to improve how medicines’ abuse risk is assessed. - Stock Titan
The FDA, Labcorp and Charles River aim to improve how medicines’ abuse risk is assessed. Stock Titan
8-K Filing: MYRIAD GENETICS INC (MYGN) (CIK 0000899923) — EX-99.1
EX-99.1
8-K Filing: Mueller Water Products, Inc. (MWA) (CIK 0001350593) — 8-K
8-K
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Source: state DOL filings, aggregated via Big Local News
Localized but repeated layoffs in key R&D centers signal cost restructuring; professionals in affected locations should confirm department-level hiring plans before accepting offers.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo